Showing results (151-160 of 230) with videos related to
Sort By:
Pageof 23
Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA StudyUrsula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.Gynecologic Oncology|October 26, 2024
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summaryKathleen N Moore, Domenica Lorusso, Ana Oaknin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerUrsula A Matulonis, Suzanne Berlin, Percy Ivy, et al.European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A Matulonis, Julie Lee, Brian Lasonde, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 7, 2016
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomasLauren L Ritterhouse, Jonathan A Nowak, Kyle C Strickland, et al.The Journal of Allergy and Clinical Immunology|May 27, 2008
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 casesMariana C Castells, Nichole M Tennant, David E Sloane, et al.JAMA Oncology|July 22, 2016
Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian CancerKatharine M Esselen, Angel M Cronin, Kristin Bixel, et al.Cancer|September 17, 2013
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervixAlexi A Wright, Brooke E Howitt, Andrea P Myers, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectivesAndrew D Zelenetz, Islah Ahmed, Edward Louis Braud, et al.Pageof 23